Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Update on the management of cirrhosis - focus on cost-effective preventative strategies.

Neff GW, Kemmer N, Duncan C, Alsina A.

Clinicoecon Outcomes Res. 2013 Apr 12;5:143-52. doi: 10.2147/CEOR.S30675. Print 2013.

2.

Update on management of patients with overt hepatic encephalopathy.

Chacko KR, Sigal SH.

Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Review.

PMID:
23948621
3.

Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.

Bajaj JS.

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:11-26. doi: 10.1111/apt.13435. Review.

PMID:
26618922
4.

Presentation and complications associated with cirrhosis of the liver.

Poordad FF.

Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905. Review.

PMID:
25697811
5.

Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

El-Shabrawi MH, Kamal NM.

Paediatr Drugs. 2011 Dec 1;13(6):371-83. doi: 10.2165/11591620-000000000-00000. Review.

PMID:
21999650
6.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 May 6;(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Review.

PMID:
27153247
7.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044. doi: 10.1002/14651858.CD003044.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD003044.

PMID:
27089005
8.

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.

Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD.

J Gastroenterol Hepatol. 2013 Mar;28(3):450-5. doi: 10.1111/jgh.12070.

PMID:
23216382
9.

Management of hepatic encephalopathy in the hospital.

Leise MD, Poterucha JJ, Kamath PS, Kim WR.

Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8. Review.

10.

Cirrhosis and chronic liver failure: part II. Complications and treatment.

Heidelbaugh JJ, Sherbondy M.

Am Fam Physician. 2006 Sep 1;74(5):767-76. Review.

11.

The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis.

Sauerbruch T, Appenrodt B, Schmitz V, Spengler U.

Dtsch Arztebl Int. 2013 Feb;110(8):126-32, I. doi: 10.3238/arztebl.2013.0126. Epub 2013 Feb 22. Review.

12.

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.

Huang E, Esrailian E, Spiegel BM.

Aliment Pharmacol Ther. 2007 Oct 15;26(8):1147-61.

13.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.

Transplant Proc. 2006 Dec;38(10):3552-5.

PMID:
17175328
14.

Wilson disease: symptomatic liver therapy.

Pfeiffenberger J, Weiss KH, Stremmel W.

Handb Clin Neurol. 2017;142:205-209. doi: 10.1016/B978-0-444-63625-6.00017-3.

PMID:
28433104
15.

Complications of cirrhosis.

Rahimi RS, Rockey DC.

Curr Opin Gastroenterol. 2012 May;28(3):223-9. doi: 10.1097/MOG.0b013e328351d003. Review.

PMID:
22343347
16.

Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T.

J Gastroenterol. 2016 Jul;51(7):629-50. doi: 10.1007/s00535-016-1216-y. Epub 2016 May 31. Review.

PMID:
27246107
17.
18.

Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model.

Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B.

Am J Gastroenterol. 2003 Apr;98(4):763-70.

PMID:
12738453
19.

Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.

Prakash RK, Kanna S, Mullen KD.

Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22. Review.

PMID:
23972578
20.

[Prevention of hepatic encephalopathy].

Morillas RM, Sala M, Planas R.

Med Clin (Barc). 2014 Jun 6;142(11):512-4. doi: 10.1016/j.medcli.2013.11.027. Epub 2014 Jan 28. Review. Spanish.

PMID:
24480288

Supplemental Content

Support Center